Loading...
XJPX4521
Market cap1.03bUSD
Jan 17, Last price  
4,262.00JPY
1D
0.24%
1Q
10.30%
Jan 2017
-31.26%
Name

Kaken Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4521 chart
P/E
20.11
P/S
2.24
EPS
211.89
Div Yield, %
3.50%
Shrs. gr., 5y
-1.10%
Rev. gr., 5y
-5.21%
Revenues
72.04b
-1.29%
74,923,000,00075,525,000,00076,414,000,00079,944,000,00082,927,000,00085,026,000,00086,433,000,00087,994,000,00087,047,000,00088,949,000,00093,895,000,000109,218,000,000101,991,000,00098,432,000,00094,167,000,00089,234,000,00074,979,000,00076,034,000,00072,984,000,00072,044,000,000
Net income
8.03b
+47.52%
3,417,000,0003,886,000,0004,602,000,0005,106,000,0005,579,000,0006,734,000,0008,213,000,0008,282,000,0008,991,000,0009,735,000,00012,122,000,00021,143,000,00022,017,000,00019,043,000,00017,775,000,00019,370,000,00013,405,000,0009,549,000,0005,440,000,0008,025,000,000
CFO
2.58b
-72.15%
8,477,000,0006,346,000,00011,933,000,00010,014,000,0008,472,000,00011,049,000,00013,142,000,00010,285,000,00011,729,000,00013,663,000,00014,737,000,00027,067,000,00015,327,000,00021,703,000,00021,129,000,00027,468,000,00014,380,000,00013,336,000,0009,253,000,0002,577,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 04, 2025

Profile

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
URL
https://www.kaken.co.jp/
IPO date
Oct 02, 1961
Employees
1,130
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
72,044,000
-1.29%
72,984,000
-4.01%
76,034,000
1.41%
Cost of revenue
62,213,000
49,217,000
42,878,000
Unusual Expense (Income)
NOPBT
9,831,000
23,767,000
33,156,000
NOPBT Margin
13.65%
32.56%
43.61%
Operating Taxes
1,770,000
1,377,000
4,336,000
Tax Rate
18.00%
5.79%
13.08%
NOPAT
8,061,000
22,390,000
28,820,000
Net income
8,025,000
47.52%
5,440,000
-43.03%
9,549,000
-28.77%
Dividends
(5,657,000)
(5,649,000)
(5,714,000)
Dividend yield
4.33%
4.07%
3.87%
Proceeds from repurchase of equity
(1,340,000)
(2,414,000)
BB yield
0.97%
1.63%
Debt
Debt current
2,168,000
3,850,000
3,850,000
Long-term debt
Deferred revenue
Other long-term liabilities
6,897,000
6,884,000
5,580,000
Net debt
(83,688,000)
(90,722,000)
(89,645,000)
Cash flow
Cash from operating activities
2,577,000
9,253,000
13,336,000
CAPEX
(2,167,000)
(2,206,000)
(3,257,000)
Cash from investing activities
(5,854,000)
(2,627,000)
(7,888,000)
Cash from financing activities
(5,658,000)
(6,990,000)
(8,129,000)
FCF
(7,078,000)
32,146,000
26,247,000
Balance
Cash
65,324,000
74,260,000
74,624,000
Long term investments
20,532,000
20,312,000
18,871,000
Excess cash
82,253,800
90,922,800
89,693,300
Stockholders' equity
160,906,000
286,823,000
288,523,000
Invested Capital
72,248,200
47,257,200
55,623,700
ROIC
13.49%
43.53%
57.10%
ROCE
6.28%
16.98%
22.47%
EV
Common stock shares outstanding
37,737
37,571
37,978
Price
3,459.00
-6.39%
3,695.00
-5.01%
3,890.00
-10.27%
Market cap
130,532,283
-5.97%
138,824,845
-6.03%
147,734,420
-11.69%
EV
46,844,283
180,048,845
191,560,420
EBITDA
12,584,000
26,335,000
35,642,000
EV/EBITDA
3.72
6.84
5.37
Interest
17,000
17,000
17,000
Interest/NOPBT
0.17%
0.07%
0.05%